Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Sells $309,521.21 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Yvonne Greenstreet also recently made the following trade(s):

• On Tuesday, November 26th, Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $252.49 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The company has a fifty day simple moving average of $254.04 and a two-hundred day simple moving average of $263.12. The firm has a market capitalization of $32.69 billion, a P/E ratio of -116.36 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on ALNY. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Barclays raised their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Canaccord Genuity Group raised their price objective on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a research note on Tuesday. StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Finally, Needham & Company LLC reissued a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $299.48.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Allworth Financial LP increased its stake in Alnylam Pharmaceuticals by 6.8% in the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 38 shares during the period. Investment Management Corp of Ontario increased its stake in Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company’s stock worth $1,670,000 after buying an additional 40 shares during the period. Nixon Peabody Trust Co. increased its stake in Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after buying an additional 43 shares during the period. Brevan Howard Capital Management LP increased its stake in Alnylam Pharmaceuticals by 3.4% in the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 44 shares during the period. Finally, Huntington National Bank increased its stake in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.